In Kampala, the capital of Uganda, a peculiar diagnostic divide has emerged in the fight against prostate cancer. Public hospitals, where the majority of men seek care, face months-long queues for prostate biopsies, a procedure essential for confirming cancer. Meanwhile, MRI machines, which could aid in staging and treatment planning, sit unused for weeks at a time, their maintenance contracts lapsed and their operators reassigned. This mismatch between available technology and the actual bottleneck in diagnosis is not a simple story of resource scarcity. It reflects how health systems allocate effort, where training and supply chains fail, and what happens when high-tech equipment outpaces the basic pathology services that make it useful.

The Diagnostic Divide in Kampala's Public Hospitals

Prostate cancer is one of the most common cancers among men in Uganda, with incidence rates that have been rising over the past two decades, according to the Kampala Cancer Registry, which reported an age-standardized incidence rate of 43.2 per 100,000 men in 2019, up from 31.1 in 2009. Yet the diagnostic pathway in public facilities remains stubbornly slow. At Mulago National Referral Hospital, the country's largest public hospital, men with elevated prostate-specific antigen (PSA) tests often wait between 10 and 16 weeks for a transrectal ultrasound-guided biopsy. The procedure itself is not complex, but it requires a urologist, biopsy needles, and pathology services to interpret the samples. Each of these components is in short supply.

In contrast, private clinics in Kampala's upscale neighborhoods offer same-day biopsies, with results available within a week. Wealthy patients, or those with international health insurance, can bypass the public queue entirely. They also have access to MRI scans for staging, which help determine whether cancer has spread beyond the prostate. These scans are performed on machines that, in public hospitals, are often idle. The irony is not lost on clinicians: a machine that could guide targeted biopsies or assess tumor extent sits unused, while men wait for a basic biopsy that does not require advanced imaging at all.

The scarcity of pathology services is the true bottleneck. Uganda has fewer than 30 pathologists for a population of over 45 million, a ratio that is among the lowest in the world. Most of these pathologists work in Kampala, leaving rural hospitals without any local capacity to read biopsy slides. Even in the capital, the pathology laboratory at Mulago processes thousands of samples a year, but the demand outstrips capacity. Biopsy samples can sit in formalin for weeks before a pathologist has time to examine them, delaying the diagnosis and, consequently, treatment. This divide is not merely a matter of convenience. Delays in diagnosis allow prostate cancer to progress from a localized, treatable disease to an advanced, metastatic one. In Uganda, a significant proportion of men are diagnosed at stage IV, when curative treatment is no longer possible. The public hospitals' inability to deliver timely biopsies thus condemns many men to a worse outcome, even though the technology to do better exists within the same city.

Why MRI Scans Sit Unused While Biopsies Are Delayed

To understand why MRI machines lie idle, one must recognize what they can and cannot do. An MRI can visualize the prostate gland and surrounding tissues, but it cannot confirm a cancer diagnosis. Only a biopsy, which involves taking small tissue samples and examining them under a microscope, can definitively establish the presence of malignant cells. Therefore, even if a patient undergoes an MRI, a biopsy is still necessary. In a resource-constrained setting, investing in imaging without strengthening biopsy and pathology services is like building a highway to a town with no houses.

Maintenance contracts are another factor. MRI machines are delicate, expensive to maintain, and require specialized technicians. When a machine breaks down in a public hospital, the repair can take months because spare parts must be imported and paid for in foreign currency. In some cases, the contracts lapse entirely, and the machine becomes a permanent fixture in the radiology department, covered in dust. At the same time, the consumables needed for biopsies, such as needles and formalin, are often out of stock due to procurement failures. A 2024 report by the Uganda Cancer Institute noted that stockouts of biopsy needles were a recurring problem, forcing procedures to be postponed or cancelled.

Clinical guidelines also play a role. In many public hospitals, the standard of care for suspected prostate cancer does not include routine MRI. Instead, clinicians rely on PSA levels, digital rectal examinations, and ultrasound-guided biopsies. MRI is reserved for staging after a biopsy has confirmed cancer, but even then, it is often unavailable or unaffordable. As a result, the machines are used less frequently, and when they are used, it is for patients who can pay out of pocket or who have private insurance.

There is also a training gap. Radiologists and technicians who operate MRI machines are few in number, and many have been trained abroad or in private facilities. In public hospitals, the few available staff are stretched thin, covering multiple imaging modalities. When a machine is idle, it is often because there is no one to operate it, not because there is no demand. This is a common pattern in low-income countries, where equipment donations outpace the human resources to use them.

The Biology of Prostate Cancer and Early Detection

Prostate cancer is typically a slow-growing malignancy, but it can be aggressive in a subset of men. The PSA test, a simple blood test, measures a protein produced by the prostate gland. Elevated levels can indicate the presence of cancer, but they can also be caused by benign conditions like prostatic hyperplasia or infection. Therefore, a PSA test is a screening tool, not a diagnosis. Only a biopsy can confirm whether cancer cells are present, and the pathologist's report includes a Gleason score, which grades the tumor's aggressiveness on a scale from 6 to 10. This score, along with PSA levels and clinical stage, guides treatment decisions, from active surveillance to surgery or radiation.

Early detection, before the cancer has spread beyond the prostate, dramatically improves survival rates. In high-income countries, the five-year survival rate for localized prostate cancer is nearly 100%, whereas for metastatic disease it drops to around 30%. In Uganda, where screening is not widespread, many men present with advanced symptoms such as bone pain from metastases, long after the window for curative treatment has closed. The delay in biopsy, therefore, is not just an inconvenience; it is a matter of life and death.

The biology also explains why MRI can be valuable. Multiparametric MRI can detect suspicious lesions within the prostate, allowing for targeted biopsies that are more accurate than systematic sampling. In high-income countries, this approach is standard. But in Uganda, the lack of MRI expertise and the high cost (a single scan can cost several hundred thousand Ugandan shillings, a week's wages for many) mean that most men never receive this benefit. The idle machines in Kampala are a reminder of what could be possible if the system were better integrated.

Comparing Care Across the Wealth Gradient in Kampala

The disparity in prostate cancer care in Kampala is stark. At private clinics like the International Hospital Kampala, a patient can have a PSA test, an MRI, and a biopsy all within a week, with results discussed in a multidisciplinary tumor board. The cost, however, is prohibitive for most Ugandans: a single MRI can cost over 500,000 shillings, and a biopsy with pathology may cost several million shillings. Out-of-pocket expenses quickly bankrupt families, especially in a country where health insurance covers only a small fraction of the population.

Public hospitals, by contrast, offer services at a subsidized cost, but the delays and supply shortages mean that patients often have to seek care privately anyway, paying for the same services they could have received for free had they been available. A 2023 study published in the Journal of Global Oncology found that the median time from PSA test to biopsy in a public hospital in Kampala was 14 weeks, compared to 2 weeks in a private clinic. This difference translates directly into stage at diagnosis: patients in the private sector were significantly more likely to be diagnosed with localized disease.

International patients also fly into Kampala for treatment, attracted by lower costs compared to Europe or North America. They stay in private facilities, where they receive world-class care, while public hospitals struggle to serve the local population. This creates a two-tiered system that exacerbates inequity. The Ugandan government has recognized this problem, but progress is slow. The National Cancer Control Plan, updated in 2022, emphasizes early detection, but funding remains inadequate.

The wealth gradient is not just about money. It also reflects differences in information and agency. Wealthier men are more likely to undergo regular health check-ups, to know about PSA testing, and to demand timely referrals. Poorer men, often in rural areas, may never see a doctor until symptoms are severe. By the time they reach a referral hospital, the disease has often progressed. This is a fundamental failure of the health system to reach the most vulnerable.

Systemic Failures: Training, Equipment, and Funding

The root causes of this diagnostic divide are systemic. The shortage of pathologists is perhaps the most critical. Uganda has roughly 0.5 pathologists per million population, compared to over 50 per million in the United States. Training new pathologists takes years and requires funding for residency programs, which are few. The Uganda Cancer Institute has tried to address this by training clinical officers to perform biopsies, but this task-shifting is not yet widespread.

Equipment donations, while well-intentioned, often fail because of a lack of spare parts and technical expertise. A 2020 survey by the Ministry of Health found that over 30% of medical equipment in public hospitals was out of service, often for minor issues that could be fixed with basic maintenance. The MRI machines in Kampala are a case in point: some have been non-functional for over a year, awaiting a technician who has not been hired.

Budget priorities also skew toward drugs rather than diagnostics. The national health budget allocates a significant portion to antiretrovirals and other essential medicines, but little to laboratory equipment or pathology services. This reflects a broader global trend, where vertical disease programs (like HIV and TB) receive substantial funding, while horizontal health system strengthening, including cancer diagnostics, lags behind. The World Health Organization has highlighted this gap, noting that non-communicable diseases are underfunded relative to their burden.

What Could Change: Practical Steps for Uganda

Despite the grim picture, there are practical steps that could improve the situation. Task-shifting, already used in HIV care, could be expanded to prostate biopsy. Clinical officers, who have less training than doctors but more than nurses, can be trained to perform biopsies under supervision. This has been done successfully in several sub-Saharan African countries, including Kenya and Tanzania, and could reduce the burden on urologists. However, task-shifting carries risks: clinical officers may lack the experience to handle complications, and without adequate supervision, the quality of biopsies could suffer. Additionally, this approach requires changes in regulations and training curricula, which can take years to implement.

Mobile pathology units, equipped with basic laboratory equipment and powered by solar energy, could bring diagnostic services to rural areas. These units would need to be connected to a network of telemedicine, where slides are digitized and sent to pathologists in Kampala or abroad for reading. This approach has been piloted for cervical cancer screening and could be adapted for prostate cancer. Yet mobile units are expensive to procure and maintain, and their effectiveness depends on reliable internet connectivity, which is often lacking in rural Uganda. Moreover, telepathology requires high-resolution scanners and trained technicians, adding to the cost.

Public-private partnerships could also address the maintenance issue. For example, a partnership with a company like Siemens or GE could provide service contracts for MRI machines in exchange for guaranteed utilization. Alternatively, the government could negotiate bulk pricing for biopsy needles and other consumables, reducing stockouts. But such partnerships are not without challenges: they may create dependencies on private companies, and the terms of service contracts can be unfavorable if not carefully negotiated. Furthermore, bulk purchasing requires efficient supply chain management, which has historically been a weak point in the public sector.

Advocacy is equally important. Civil society organizations, such as the Uganda Non-Communicable Disease Alliance, have been pushing for increased health funding and better cancer care. Their efforts have led to some policy changes, such as the inclusion of cancer care in the universal health coverage agenda. But sustained pressure is needed to ensure that diagnostics are prioritized alongside treatment. Advocacy alone, however, cannot overcome the structural barriers of inadequate funding and human resources; it must be coupled with technical solutions and political will.

The Cost of Inaction and a Path Forward

The cost of inaction is measured not only in lives lost but also in the financial strain on the health system. Late-stage prostate cancer requires expensive treatments, including hormone therapy, chemotherapy, and palliative care, which are far more costly than early diagnosis and surgery. A 2021 study estimated that the economic burden of prostate cancer in Uganda was over 20 billion shillings annually, most of it due to advanced disease. Investing in diagnostics could reduce this burden by catching cancers early.

Policy changes must align with clinical reality. It may seem counterintuitive to prioritize basic diagnostics over advanced imaging, but without a functioning biopsy and pathology pathway, MRI machines remain decorative. The Ugandan government, with support from international partners, should prioritize strengthening the entire diagnostic pathway, from PSA testing to biopsy to pathology. This requires a coordinated approach that addresses training, equipment, and supply chain simultaneously.

However, such an approach faces significant hurdles. The proposed solutions, while promising, are not without trade-offs. Task-shifting, for instance, could lead to a dilution of skills if not properly supervised. Mobile pathology units require substantial upfront investment and ongoing maintenance, which may divert funds from other pressing needs. Public-private partnerships might not be feasible in all settings, especially where governance is weak. Critics also argue that focusing on diagnostics without addressing the broader health system constraints, such as the shortage of urologists and oncologists, may yield limited benefits. Moreover, the cost of scaling up these interventions could be prohibitive, and international donors may be reluctant to fund long-term capacity building.

Community awareness is also crucial. Many men in Uganda do not know about prostate cancer or the importance of early detection. Outreach programs, using radio and community health workers, could encourage men over 40 to get a PSA test. This is particularly important in rural areas, where access to healthcare is limited. International collaboration, such as twinning programs with academic institutions in Europe or North America, can provide training and technical support.

None of these solutions are quick or easy. They require sustained political will and financial investment. But the alternative, allowing the diagnostic divide to persist, is untenable. Every week of delay in a biopsy is a week that a man's cancer can spread. The idle MRI machines in Kampala are a symbol of misplaced priorities, but they also represent an opportunity. If the system can be reoriented to use them effectively, in conjunction with a strengthened biopsy and pathology service, the outcome for men in Uganda could be transformed.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.